JP2011515073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515073A5 JP2011515073A5 JP2010547002A JP2010547002A JP2011515073A5 JP 2011515073 A5 JP2011515073 A5 JP 2011515073A5 JP 2010547002 A JP2010547002 A JP 2010547002A JP 2010547002 A JP2010547002 A JP 2010547002A JP 2011515073 A5 JP2011515073 A5 JP 2011515073A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 30
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 18
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 18
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 17
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 17
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 230000002134 immunopathologic effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 230000009460 calcium influx Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6653908P | 2008-02-20 | 2008-02-20 | |
| US61/066,539 | 2008-02-20 | ||
| PCT/AU2009/000184 WO2009103113A1 (en) | 2008-02-20 | 2009-02-19 | HUMANIZED ANTI-C5aR ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014092573A Division JP6034826B2 (ja) | 2008-02-20 | 2014-04-28 | ヒト化抗Ｃ５ａＲ抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011515073A JP2011515073A (ja) | 2011-05-19 |
| JP2011515073A5 true JP2011515073A5 (OSRAM) | 2012-04-05 |
Family
ID=40984994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547002A Pending JP2011515073A (ja) | 2008-02-20 | 2009-02-19 | ヒト化抗Ｃ５ａＲ抗体 |
| JP2014092573A Expired - Fee Related JP6034826B2 (ja) | 2008-02-20 | 2014-04-28 | ヒト化抗Ｃ５ａＲ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014092573A Expired - Fee Related JP6034826B2 (ja) | 2008-02-20 | 2014-04-28 | ヒト化抗Ｃ５ａＲ抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8268972B2 (OSRAM) |
| EP (2) | EP2254911B1 (OSRAM) |
| JP (2) | JP2011515073A (OSRAM) |
| KR (1) | KR20100117120A (OSRAM) |
| CN (2) | CN101970494B (OSRAM) |
| AU (1) | AU2009217224B2 (OSRAM) |
| BR (1) | BRPI0907532A2 (OSRAM) |
| CA (1) | CA2714296A1 (OSRAM) |
| ES (1) | ES2562627T3 (OSRAM) |
| IL (1) | IL207217A (OSRAM) |
| MX (1) | MX2010009190A (OSRAM) |
| RU (1) | RU2010138612A (OSRAM) |
| WO (1) | WO2009103113A1 (OSRAM) |
| ZA (1) | ZA201005348B (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1642983A (zh) | 2002-01-25 | 2005-07-20 | G2治疗有限公司 | 抗C5aR抗体及其应用 |
| CN104059149B (zh) * | 2006-08-22 | 2017-04-12 | 诺沃诺蒂斯克股份有限公司 | 具有改进性能的抗‑C5aR抗体 |
| CN101970494B (zh) | 2008-02-20 | 2015-01-21 | G2炎症私人有限公司 | 人源化抗-C5aR抗体 |
| JP2011526591A (ja) | 2008-06-30 | 2011-10-13 | ノボ・ノルデイスク・エー／エス | 抗ヒトインターロイキン−２０抗体 |
| PT2334705T (pt) * | 2008-09-26 | 2017-03-22 | Ucb Biopharma Sprl | Produtos biológicos |
| US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| EA201892184A1 (ru) | 2010-03-01 | 2019-03-29 | БАЙЕР ХЕЛЬСКЕР ЛЛСи | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора |
| US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
| EP2468295A1 (en) | 2010-12-21 | 2012-06-27 | Affiris AG | Vaccines based on peptides of the complement protein C5a |
| DK3424953T3 (en) | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
| WO2014015133A1 (en) | 2012-07-19 | 2014-01-23 | National Cheng Kung University | Treatment of osteoarthritis using il-20 antagonists |
| US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
| US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| GB201220242D0 (en) * | 2012-11-09 | 2012-12-26 | Fusion Antibodies Ltd | Antibody |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2994488B1 (en) * | 2013-05-08 | 2022-07-13 | Novo Nordisk A/S | Use of c5ar antagonists |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| EP3699198B1 (en) | 2014-11-17 | 2025-03-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
| KR20170094787A (ko) * | 2014-12-18 | 2017-08-21 | 에프. 호프만-라 로슈 아게 | Cdc 유발 항체를 측정하기 위한 검정 및 방법 |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| CN107849133B (zh) | 2015-05-04 | 2022-08-23 | 西托姆克斯治疗公司 | 抗cd166抗体、可活化抗cd166抗体及其使用方法 |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| MX2019011252A (es) * | 2017-03-23 | 2020-01-23 | Univ Pennsylvania | Anticuerpos anti-c5a y usos de los mismos. |
| JP2020531045A (ja) * | 2017-07-14 | 2020-11-05 | シートムエックス セラピューティクス，インコーポレイテッド | 抗ｃｄ１６６抗体およびその使用 |
| KR102355755B1 (ko) * | 2017-12-14 | 2022-02-08 | 코카 크롬 인더스트리 컴퍼니 리미티드 | 냉각롤 및 그것을 사용한 열가소성 수지 시트의 제조 방법 |
| MA52808A (fr) * | 2018-06-07 | 2021-04-14 | Chemocentryx Inc | Dosage et effet d'un antagoniste de c5a avec une vasculite associée aux anca |
| DK3844189T3 (da) | 2018-08-31 | 2025-02-24 | Regeneron Pharma | Doseringsstrategi, der mindsker cytokinfrigivelsessyndrom for CD3/CD20-bispecifikke antistoffer |
| CN109439662B (zh) * | 2018-11-15 | 2020-09-01 | 北京大学第三医院 | 用于C5aR1基因敲除的sgRNA、载体以及构建方法和检测方法 |
| BR112021017860A2 (pt) * | 2019-03-14 | 2021-12-07 | Morphosys Ag | Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| KR20230142831A (ko) | 2021-01-13 | 2023-10-11 | 비스테라, 인크. | 인간화된 보체 5a 수용체 1 항체 및 이의 사용 방법 |
| WO2024193714A1 (zh) * | 2023-03-23 | 2024-09-26 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4098876A (en) * | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| JPH02262599A (ja) | 1989-01-03 | 1990-10-25 | Merck & Co Inc | ヒト多形核白血球からの精製Ｃ５ａレセプター |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5284746A (en) * | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| EP0672068A4 (en) | 1992-09-25 | 1997-02-26 | Commw Scient Ind Res Org | TARGET MOLECULES BINDING POLYPEPTIDES. |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5480974A (en) | 1993-06-18 | 1996-01-02 | The Scripps Research Institute | Antibodies to human C5a receptor |
| US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5861272A (en) * | 1995-06-02 | 1999-01-19 | Human Genome Sciences, Inc. | C5A receptor |
| JPH08109200A (ja) | 1994-08-19 | 1996-04-30 | Takeda Chem Ind Ltd | 抗Ｃ５ａレセプター抗体、その製造法および用途 |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| CA2223038A1 (en) | 1995-06-05 | 1996-12-12 | Jeffrey J. Seilhamer | A c5a-like seven transmembrane receptor |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| EP0972027A1 (en) | 1997-01-31 | 2000-01-19 | Incyte Pharmaceuticals, Inc. | Human c5a-like receptor |
| WO1998049198A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| WO2002038767A2 (en) | 2000-11-07 | 2002-05-16 | Genetics Institute, Llc. | G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
| EP1409646B1 (en) | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
| WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| WO2003027252A2 (en) | 2001-09-27 | 2003-04-03 | Merck & Co., Inc. | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| CN1642983A (zh) | 2002-01-25 | 2005-07-20 | G2治疗有限公司 | 抗C5aR抗体及其应用 |
| WO2004040000A2 (en) | 2002-09-09 | 2004-05-13 | Nura, Inc | G protein coupled receptors and uses thereof |
| MXPA05005921A (es) | 2002-12-02 | 2005-10-19 | Abgenix Inc | Anticuerpos dirigidos a factor de necrosis tumoral y sus usos. |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| EP1701611B1 (en) | 2003-12-24 | 2011-05-18 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| BRPI0509264A (pt) * | 2004-03-26 | 2007-09-04 | Promics Pty Ltd | tratamento de condições neurológicas que usa moduladores de receptor c5a de complemento |
| SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| US7649951B2 (en) | 2006-08-16 | 2010-01-19 | Harris Corporation | System and method for communicating data using symbol-based randomized orthogonal frequency division multiplexing (OFDM) with applied frequency domain spreading |
| CN104059149B (zh) | 2006-08-22 | 2017-04-12 | 诺沃诺蒂斯克股份有限公司 | 具有改进性能的抗‑C5aR抗体 |
| CN101501073A (zh) | 2006-08-22 | 2009-08-05 | G2英弗勒美欣私人有限公司 | 抗体制备方法 |
| WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
| ES2400107T3 (es) | 2007-10-22 | 2013-04-05 | Merck Serono S.A. | IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado |
| CN101970494B (zh) | 2008-02-20 | 2015-01-21 | G2炎症私人有限公司 | 人源化抗-C5aR抗体 |
| WO2010000864A1 (en) | 2008-07-04 | 2010-01-07 | Novo Nordisk A/S | Method for producing monoclonal antibodies |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
-
2009
- 2009-02-19 CN CN200980105691.9A patent/CN101970494B/zh not_active Expired - Fee Related
- 2009-02-19 CN CN201410315627.6A patent/CN104193824A/zh not_active Withdrawn
- 2009-02-19 KR KR1020107020742A patent/KR20100117120A/ko not_active Ceased
- 2009-02-19 WO PCT/AU2009/000184 patent/WO2009103113A1/en not_active Ceased
- 2009-02-19 AU AU2009217224A patent/AU2009217224B2/en not_active Ceased
- 2009-02-19 JP JP2010547002A patent/JP2011515073A/ja active Pending
- 2009-02-19 US US12/866,009 patent/US8268972B2/en not_active Expired - Fee Related
- 2009-02-19 EP EP09713373.0A patent/EP2254911B1/en not_active Not-in-force
- 2009-02-19 ES ES09713373.0T patent/ES2562627T3/es active Active
- 2009-02-19 EP EP14177321.8A patent/EP2826791A3/en not_active Withdrawn
- 2009-02-19 MX MX2010009190A patent/MX2010009190A/es active IP Right Grant
- 2009-02-19 CA CA2714296A patent/CA2714296A1/en not_active Abandoned
- 2009-02-19 BR BRPI0907532-1A patent/BRPI0907532A2/pt not_active Application Discontinuation
- 2009-02-19 RU RU2010138612/10A patent/RU2010138612A/ru not_active Application Discontinuation
-
2010
- 2010-07-26 IL IL207217A patent/IL207217A/en not_active IP Right Cessation
- 2010-07-27 ZA ZA2010/05348A patent/ZA201005348B/en unknown
-
2012
- 2012-08-20 US US13/590,016 patent/US8361468B2/en not_active Expired - Fee Related
- 2012-12-19 US US13/720,685 patent/US8808701B2/en not_active Expired - Fee Related
-
2014
- 2014-04-28 JP JP2014092573A patent/JP6034826B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011515073A5 (OSRAM) | ||
| MX2025003227A (es) | Anticuerpo anti-interleucina-17a, composicion farmaceutica y uso de los mismos | |
| RU2010138612A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR | |
| RU2021124437A (ru) | Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования | |
| JP2009518005A5 (OSRAM) | ||
| RU2012147591A (ru) | Антитела к erbb3 | |
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ599140A (en) | Antibodies that specifically bind to the epha2 receptor | |
| IL259927B1 (en) | Humanized antibodies against cd73 | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| JP2017523786A5 (OSRAM) | ||
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| TR201817932T4 (en) | ANTIBODIES THAT BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN SPECIFICALLY AND METHODS OF USE | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
| JP2015532644A5 (OSRAM) | ||
| JP2012254083A5 (OSRAM) | ||
| TR201815254T4 (tr) | Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari | |
| JP2015529236A5 (OSRAM) | ||
| JP2014508748A5 (OSRAM) | ||
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| RU2013141956A (ru) | Антитело против ксф-1r | |
| RU2014120694A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К iNKT | |
| JP2011524741A5 (OSRAM) | ||
| JP2017507657A5 (OSRAM) |